Location History:
- København Ø, DK (2001)
- Copenhagen, DK (2004 - 2020)
Company Filing History:
2 out of 24 
1 out of 1 
1 out of 1 Years Active: 2001-2020
Title: Maxwell Sehested: Innovator in Cancer Treatment
Introduction
Maxwell Sehested is a prominent inventor based in Copenhagen, Denmark. He has made significant contributions to the field of cancer treatment through his innovative research and development of combination therapies. With a total of five patents to his name, Sehested is recognized for his work in utilizing histone deacetylase (HDAC) inhibitors in cancer therapies.
Latest Patents
One of his latest patents focuses on combination therapies using HDAC inhibitors. This invention pertains to a method for treating various types of cancer, including lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer. The method involves administering a first amount of an HDAC inhibitor, such as PXD-101, alongside a second amount of another chemotherapeutic agent, like dexamethasone or 5-fluorouracil. The combination aims to provide a therapeutically effective amount for patients in need.
Career Highlights
Throughout his career, Maxwell Sehested has worked with notable companies in the pharmaceutical industry, including Topotarget UK Limited and Topo Target Aps. His experience in these organizations has contributed to his expertise in developing innovative cancer treatments.
Collaborations
Sehested has collaborated with esteemed colleagues in the field, including Peter Buhl Jensen and Henri Lichenstein. These partnerships have further enhanced his research and development efforts in cancer therapies.
Conclusion
Maxwell Sehested's contributions to cancer treatment through his innovative patents and collaborations highlight his dedication to improving patient outcomes. His work continues to influence the field of oncology and offers hope for more effective cancer therapies in the future.